Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Teva Pharmaceuticals presented interim results from the FINESSE study at the German Society of Neurology (DGN) Congress 2021. The study evaluates the effectiveness of fremanezumab in chronic and episodic migraine patients. Data from 574 patients indicated a 48.7% achievement of the primary endpoint—a ≥ 50% reduction in migraine days after 6 months. Additionally, significant reductions in migraine days, disability scores, and acute medication use were observed. Overall, these findings align with previous Phase III studies and highlight fremanezumab's effectiveness in real-life settings.

Teva Pharmaceutical Industries Limited has achieved a legal victory as Judge Peter Wilson of the Superior Court in California ruled that Teva did not cause a public nuisance regarding opioid marketing in Orange County, Los Angeles County, Santa Clara County, and Oakland. The court also found that Teva did not engage in false or misleading advertising practices. Teva emphasizes the need for comprehensive settlements to support those affected by opioid addiction, while it remains committed to providing affordable medicines globally.

Teva Pharmaceuticals announced positive results from the Phase 3 RISE study evaluating TV-46000, a long-acting injectable risperidone formulation, aimed at treating schizophrenia. The study showed that TV-46000 significantly prolonged time to relapse and increased clinical stability compared to placebo. Among 544 randomized patients, relapse rates were dramatically lower, with only 9% at week 24 for TV-46000 users versus 28% for placebo. The safety profile was consistent with existing risperidone formulations, indicating potential enhancements in treatment options for patients suffering from this disorder.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has initiated cash tender offers totaling up to $3.5 billion for various series of senior notes due between 2022 and 2024. The goal is to manage and extend the maturity profile of its debt effectively. The offers encompass several note series, including 1.250% and 2.800% Senior Notes due 2023. The offers will expire on November 24, 2021, unless extended. Investors must act before November 9, 2021, for early tender considerations that include a premium of $30.00 per $1,000 of notes.

Teva Pharmaceutical Industries Ltd. reported third-quarter 2021 revenues of $3.9 billion, down 2% year-over-year, with a GAAP EPS of $0.26 and a non-GAAP EPS of $0.59.

Key drivers included strong sales from AJOVY® and AUSTEDO®, while lower revenues from COPAXONE® impacted results. Teva reaffirmed its full-year guidance, anticipating net revenues of $16.0 - $16.4 billion and adjusted EBITDA of $4.8 - $5.1 billion. Cash flow from operations was $529 million with $795 million in free cash flow, reflecting efficient cash management.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced a collaboration with MODAG GmbH to exclusively license and develop the small molecule candidate Anle138b, targeting neurological disorders like multiple system atrophy (MSA) and Parkinson’s disease (PD). The agreement allows Teva to develop and commercialize Anle138b and related compound Sery433, following favorable Phase 1 study results. The collaboration aims to address unmet medical needs in neurodegenerative diseases, potentially impacting thousands of patients annually.